Kronos Bio Inc (KRON)

$1.27

+0.06

(+4.96%)▲

Market is closed - opens 8 PM, 07 Dec 2023

Insights on Kronos Bio Inc

  • Vs SGEN

    In the last 1 year, Seagen, Inc. has given 80.8% return, outperforming this stock by 107.8%

  • Vs NVO

    In the last 3 years, Novo Nordisk A/s has given 20.4% return, outperforming this stock by 116.4%

Performance

  • $1.16
    $1.30
    $1.27
    downward going graph

    8.61%

    Downside

    Day's Volatility :10.71%

    Upside

    2.3%

    downward going graph
  • $0.73
    $2.84
    $1.27
    downward going graph

    42.44%

    Downside

    52 Weeks Volatility :74.26%

    Upside

    55.28%

    downward going graph

Returns

PeriodKronos Bio IncSector (Health Care)Index (Russel 2000)
3 Months
0.79%
0.0%
0.0%
6 Months
-23.49%
2.2%
0.0%
1 Year
-27.01%
-4.7%
-2.1%
3 Years
-95.98%
18.0%
-6.5%

Highlights

Market Capitalization
70.0M
Book Value
$3.07
Dividend Share
0.0
Dividend Yield
0.0%
Earnings Per Share (EPS)
-2.08
Wall Street Target Price
8.75
Profit Margin
0.0%
Operating Margin TTM
-3688.66%
Return On Assets TTM
-28.83%
Return On Equity TTM
-53.39%
Revenue TTM
4.0M
Revenue Per Share TTM
0.07
Quarterly Revenue Growth YOY
0.0%
Gross Profit TTM
0.0
EBITDA
-125.9M
Diluted Eps TTM
-2.08
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-2.03
EPS Estimate Next Year
-1.9
EPS Estimate Current Quarter
-0.51
EPS Estimate Next Quarter
-0.54

Analyst Recommendation

Buy
    90%Buy
    10%Hold
    0
    0%Sell
Based on 10 Wall street analysts offering stock ratings for Kronos Bio Inc(by analysts ranked 0 to 5 stars)
Based on 10 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
9
9
11
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 588.98%

Current $1.27
Target $8.75

Technicals Summary

Sell

Neutral

Buy

Kronos Bio Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

More on Technical Analysis

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Kronos Bio Inc
Kronos Bio Inc
48.04%
-23.49%
-27.01%
-95.98%
-95.31%
Moderna, Inc.
Moderna, Inc.
9.42%
-35.83%
-54.97%
-49.47%
333.33%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
0.6%
13.15%
9.35%
68.7%
124.16%
Novo Nordisk A/s
Novo Nordisk A/s
-4.03%
23.9%
55.84%
186.15%
330.1%
Seagen, Inc.
Seagen, Inc.
0.86%
10.81%
80.8%
20.4%
259.73%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
-6.55%
8.87%
11.3%
55.67%
105.25%
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Kronos Bio Inc
Kronos Bio Inc
NA
NA
NA
-2.03
-0.53
-0.29
0.0
3.07
Moderna, Inc.
Moderna, Inc.
24.73
NA
0.0
-12.72
-0.22
-0.07
0.0
35.32
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
23.18
23.18
1.75
42.5
0.17
0.09
0.01
234.47
Novo Nordisk A/s
Novo Nordisk A/s
41.18
41.18
4.02
2.67
0.89
0.22
0.01
20.77
Seagen, Inc.
Seagen, Inc.
NA
NA
18.53
-4.16
-0.28
-0.13
0.03
13.52
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
26.38
26.38
0.5
15.04
0.23
0.14
0.0
64.05
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin
Kronos Bio Inc
Kronos Bio Inc
Buy
$70.0M
-95.31%
NA
0.0%
Moderna, Inc.
Moderna, Inc.
Buy
$30.4B
333.33%
24.73
-38.0%
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
Buy
$88.5B
124.16%
23.18
30.47%
Novo Nordisk A/s
Novo Nordisk A/s
Buy
$459.0B
330.1%
41.18
35.11%
Seagen, Inc.
Seagen, Inc.
Hold
$40.2B
259.73%
NA
-32.61%
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
Buy
$90.5B
105.25%
26.38
35.94%

Institutional Holdings

  • Omega Fund Management LLC

    6.55%

  • Bvf Inc

    4.98%

  • Vida Ventures Advisors, LLC

    4.74%

  • Perceptive Advisors LLC

    3.01%

  • Vanguard Group Inc

    2.90%

  • PARTNERS CAPITAL INVESTMENT GROUP, LLP

    2.86%

Corporate Announcements

  • Kronos Bio Inc Earnings

    Kronos Bio Inc’s price-to-earnings ratio stands at None

    Read More

Company Information

kronos bio is dedicated to the research and development of first-in-class therapies that modulate historically recalcitrant cancer targets. leveraging industry-leading research into high-throughput screening strategies for chemical modulators of transcription factors and other challenging targets in oncology, kronos utilizes its small molecule microarray (smm) platform and extensive know-how in biological assay development to pursue novel therapies against some of the most important and intractable targets in cancer research.

Organization
Kronos Bio Inc
Employees
99
CEO
Dr. Norbert W. Bischofberger Ph.D.
Industry
Health Technology

Discover More

FAQs